Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease
(A4 Study)

What is the purpose of this research study?
The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solanezumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD). In AD, there are abnormally high levels of a protein, called amyloid in the brain. We hope that solanezumab can reduce the amount of amyloid in the brain.

Who is eligible?
We are looking for participants who:
- do not have memory problems
- are between the age 65 and 85
- have a reliable family member who knows them well
- are in stable medical condition
- are willing to undergo MRI and PET scans

What happens during the study?
During the study, we will ask the participant to come to our office for study-related physical and neurological exams, blood tests, memory and thinking tests, 4 MRI scans and at least 2 PET scans.

The study drug (or placebo) is given as an infusion through an IV (a thin, flexible plastic tube with a needle attached) into your arm. You will get these infusions every 4 weeks for 168 weeks.

How long is this study?
The study lasts for up to 176 weeks and will require about 45 visits to our site at Brigham and Women’s Hospital and 2 visits to Mass General Hospital. Each study visit will last for 1 to 5 hours.

What about placebos?
This study does use placebos (liquid that does not contain active drug). There is a 50% (1 in 2) chance of receiving Solanezumab and a 50% (1 in 2) chance of receiving placebo.

Will I be paid?
We will pay the costs of parking at our offices during your visits.

Who is sponsoring this study?
This study is being done by the Alzheimer’s Disease Cooperative Study (ADCS). They are working with Eli Lilly and Company, through a grant from the National Institute on Aging.

How do I find out more about the study?
For more information, please call us at 617-732-8085 or email our study coordinator nurse Martha Vander Vliet at mvandervliet@partners.org.